Clinical studies to implement Rheopheresis for age-related macular degeneration guided by evidence-based-medicine

Transfusion and Apheresis Science

Volumn 29, Issue 1, 2003, Pages 71-84

  Klingel, Reinhard ^a   Fassbender, Cordula ^a   Faßbender, Thurid ^a   Göhlen, Britta ^a  

^a Apheresis Research Institute   (Germany)

Author keywords

Age related macular degeneration; Drusen; Dry AMD; Membrane differential filtration; Rheopheresis; Therapeutic apheresis

Indexed keywords

ALPHA 2 MACROGLOBULIN; FIBRINOGEN; FIBRONECTIN; LOW DENSITY LIPOPROTEIN; PLASMA PROTEIN; VON WILLEBRAND FACTOR;

ADULT; AGED; APHERESIS; BIOLOGICAL THERAPY; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; EDEMA; EVIDENCE BASED MEDICINE; FEVER; HEADACHE; HEMATOMA; HUMAN; HYPOTENSION; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; MICROANGIOPATHY; PLASMA VISCOSITY; RETINA MACULA AGE RELATED DEGENERATION; RHEOPHERESIS; RISK FACTOR; SAFETY; TETANY; VERTIGO;

EID: 0038160740     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-0502(03)00101-0     Document Type: Conference Paper

References (49)

1. Pfau N., Kupsch S., Kern A.O., Beske F. Epidemiology and socioeconomic importance of blindness and severe vision loss in Germany. Schriftenreihe des IGSF - Institut für Gesundheits-System-Forschung. 84:2000;1-161. [Publication in German].
2. Ciulla T.A., Harris A., Martin B.J. Ocular perfusion and age-related macular degeneration. Acta Ophthalmol. Scand. 79:2001;108-115.
3. Fine S.L., Berger J.W., Maguire M.G., Ho A.C. Age-related macular degeneration. New Engl. J. Med. 342:2000;483-492.
4. Sarraf D., Gin T., Yu F., Brannon A., Owens S.L., Bird A.C. Long-term drusen study. Retina. 19:1999;513-519.
5. Lanchoney D.M., Maguire M.G., Fine S.L. A model of the incidence and consequences of choroidal neovascularization secondary to age-related macular degeneration. Comparative effects of current treatment and potential prophylaxis on visual outcomes in high-risk patients. Arch. Ophthalmol. 116:1998;1045-1052.
6. Klein R., Klein B.E.K., Tomany S.C., Meuer S.M., Huang G.H. Ten-year incidence and progression of age-related maculopathy. Ophthalmology. 109:2002;1767-1779.
7. Hageman G.S., Luthert P.J., Chong N.H.V., Johnson L.V., Anderson D.H., Mullins R.F. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog. Ret. Eye Res. 20:2001;705-732.
8. Ramirez J.M., Ramirez A.I., Salazar J.J., de Hoz R., Trivino A. Changes of astrocytes in retinal aging and age-related macular degeneration. Exp. Eye Res. 73:2001;601-615.
9. Eye Disease Case-Control Study Group Risk factors for neovascular age-related macular degeneration. Arch. Ophthalmol. 110:1992;1701-1708.
10. Smith W., Mitchell P., Leeder S.R., Wang J.J. Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy. Arch. Ophthalmol. 116:1998;583. 587.
11. Vingerling J.R., Dielemans I., Bots M.L., Homan A., Grobbee D.E.L., de Jong P.T.V.M. Age-related macular degeneration is associated with atherosclerosis. Am. J. Epidemiol. 142:1995;404-409.
12. Lip P.L., Blann A.D., Hope-Ross M., Gibson J.M., Lip G.Y.H. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology, and endothelial dysfunction. Ophthalmology. 108:2001;705-710.
13. Baudouin C., Peyman G.A., Fredj-Reygrobellet D., Gordon W.C., Lapalus P., Gastaud P.et al. Immunohistochemical study of subretinal membranes in age-related macular degeneration. Jpn. J. Ophthalmol. 36:1992;443-451.
14. Friedman E. A hemodynamic model of the pathogenesis of age-related macular degeneration. Am. J. Ophthalmol. 124:1997;677-682.
15. Grunwald J., Hariprasad S., DuPont J. Effect of aging on foveolar choroidal circulation. Arch. Opthalmol. 116:1998;150-154.
16. Grunwald J., Hariprasad S., DuPont J., Maguire M., Fine S., Brucker A.et al. Foveolar choroidal blood flow in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 39:1998;385-390.
17. Chen S.J., Cheng C.Y., Lee A.F., Lee F.L., Chou J.C.K., Hsu W.M.et al. Pulsatile ocular blood flow in asymmetric exudative age related macular degeneration. Br. J. Ophthalmol. 85:2001;1411-1415.
18. Tamai M., Mizuno K., Chader G.J. In vitro studies on shedding and phagocytosis of rod outer segments in the rat retina: effect of oxygen concentration. Invest. Ophthalmol. 22:1982;439-448.
19. Sheu S.J., Sakamoto T., Osusky R., Wang H.M., Ogden T.E., Ryan S.J.et al. Transforming growth factor-β regulates human retinal pigment epithelial cell phagocytosis by influencing a protein kinase C-dependent pathway. Graefe's Arch. Clin. Exp. Ophthalmol. 234:1994;695-701.
20. Ueba H., Kawakami M., Yaginuma T. Shear stress as an inhibitor of vascular smooth muscle cell proliferation. Role of transforming growth factor beta1 and tissue-type plasminogen activator. Arterioscler. Thromb. Vasc. Biol. 17:1997;1512-1516.
21. Moore D.J., Clover G.M. The effect of age on the macromolecular permeability of human Bruch's membrane. Invest. Ophthalmol. Vis. Sci. 42:2001;2970-2975.
22. King G.L., Suzuma K. Pigment-epithelium-derived factor - a key coordinator of retinal neuronal and vascular functions. New Engl. J. Med. 342:2000;349-351.
23. Hussain A.A., Rowe L., Marshall J. Age-related alterations in the diffusional transport of amino acids across the human Bruch's-choroid complex. J. Opt. Soc. Am. A Opt. Image Sci. Vis. 19:2002;166-172.
24. Preissner K.T., Pötsch B. Vessel wall-dependent metabolic pathways of the adhesive proteins von-Willebrand factor and vitronectin. Histol. Histopathol. 10:1995;239-251.
25. Stockmann A., Hess S., Declerck P., Timpl R., Preissner K.T. Multimeric vitronectin. J. Biol. Chem. 268:1993;22874-22882.
26. Kost C., Benner K., Stockmann A., Linder D., Preissner K.T. Limited plasmin proteolysis of vitronectin - characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor. Eur. J. Biochem. 236:1996;682-688.
27. Hammes H.P., Brownlee M., Jonczyk A., Sutter A., Preissner K.T. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nature Med. 2:1996;529-533.
28. Johnson L.V., Leitner W.P., Staples M.K., Anderson D.H. Complement activation and inflasmmatory processes in drusen formation and age related macular degeneration. Exp. Eye Res. 73:2001;887-896.
29. Age-Related Eye Disease Study Research Group A randomized, placebo-controled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch. Ophthalmol. 119:2001;1417-1436.
30. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Three-year results of an open-label extension of 2 randomized clinical trials - TAP report no. 5. Arch. Ophthalmol. 120:2002;1307-1314.
31. Currie Z.I., Rennie I.G., Talbot J.F. Retinal vascular changes associated with transpupillary thermotherapy for choroidal melanomas. Retina. 20:2000;620-626.
32. Guymer R.H., Hageman G.S., Bird A.C. Influence of laser photocoagulation on choroidal capillary cytoarchitecture. Br. J. Ophthalmol. 85:2001;40-46.
33. Kaga T., Fonseca R.A., Dantas M.A., Spaide R.F. Transient appearance of classic choroidal neovascularization after transpupillary thermotherapy for occult choroidal neovascularization. Retina. 21:2001;172-173.
34. Kaiser R.S., Berger J.W., Maguire M.G., Ho A.C., Javornik N.B. Laser burn intensity and the risk for choroidal neovascularization in the CNVPT fellow eye study. Arch. Ophthalmol. 119:2001;826-832.
35. Klingel R., Fassbender C., Faßbender T., Erdtracht B. Rheopheresis - rheologic, functional and structural aspects. Therap. Apher. 4:2000;348-357.
36. Küstner E., Himmelsbach F., Mumme C., Altes U., Klingel R., Beyer J. Rheopheresis in patients with ischemic diabetic foot syndrome - first results of a pilot trial. Kidney Blood Pressure Res. 24:2001;236. [abstract].
37. Lüke C., Widder R.A., Soudavar F., Walter P., Brunner R., Borberg H. Improvement of macular function by membrane differential filtration in diabetic retinopathy. J. Clin. Apher. 16:2001;23-28.
38. Brunner R., Widder R.A., Walter P., Lüke C., Godehardt E., Bartz-Schmidt K.-U.et al. Influence of membrane differential filtration on the natural course of age-related macular degeneration - a randomized trial. Retina. 20:2000;483-491.
39. Swartz M., Rabetoy G. Treatment of non-exudative age-related macular degeneration using membrane differential filtration apheresis. Invest. Ophthalmol. Vis. Sci. 40:1999;319. [abstract].
40. Brunner R., Widder R.A., Fischer R.A., Walter P., Bartz-Schmidt K.-U., Heimann K. Clinical efficacy of haemorheological treatment using plasma exchange, selective adsorption and membrane differential filtration in maculopathy, retinal vein occlusion and uveal effusion syndrome. Transfus. Sci. 17:1996;493-498.
41. Soudavar F., Widder R.A., Brunner R., Walter P., Bartz-Schmitz K.U., Borberg H.et al. Changes of retinal haemodynamics after elimination of high molecular weight proteins and lipids in patients with age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 39:1998;386. [abstract].
42. Fell A., Engelmann K., Richard G., Fassbender C., Wahls W., Klingel R. Rheopheresis - a sytemic approach to therapy of age-related macular degeneration. Ophthalmologe. 99:2002;780-784.
43. Abdelsalam A., Del Priore L., Zarbin M.A. Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Surv. Ophthalmol. 44:1998;1-29.
44. Widder R.A., Farvili E., Reis R.G.J., Lüke C., Walter P., Kirchhof B.et al. The treatment of age-related macular degeneration (ARMD) with extracorporeal treatment procedures. A follow-up of four years. Invest. Ophthalmol. Vis. Sci. 43:2002;2906. [abstract].
45. Godehardt E, Messner H, Wallstab UH. Extracorporeal LDL cholesterol elimination by membrane differential filtration. In: Gotto AM, Mancini M, Richter WO, Schwandt P, editors. Treatment of severe dyslipoproteinemia in the prevention of coronary heart disease, vol. 4, 1993. p. 208-12.
46. Berrouschot J., Barthel H., Scheel C., Köster J., Schneider D. Extracorporeal membrane differential filtration - a new and safe method to optimize hemorheology in acute ischemic stroke. Acta Neurol. Scand. 97:1998;126-130.
47. Suckfüll M for the Hearing Loss Study Group Fibrinogen and LDL-apheresis in treatment of sudden hearing loss: a randomized multicentre trial. Lancet. 360:2002;1811-1817.
48. Ohno-Matsui K., Morita I., Tombran-Tink J., Mrazek D., Onodera M., Uetama T.et al. Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J. Cell. Physiol. 189:2001;323-333.
49. Mann H., Bosch Th., Braun N., Fassbinder W., Klingel R., Klinkmann J. Apheresis-standard of the German society for clinical nephrology. Mitteilungen der Deutschen Arbeitsgemeinschaft für Klinische Nephrologie. XXXI:2002;103-138. [Article in German].